1. Norway Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Thor Medical ASA

Thor Medical ASA

4.31
NOK
-0.07
(-1.54%)
-4.01EPS
292.52MMarket Cap
Mar 03Next Earn
Thor Medical ASA
IOB:0R6Y
(London Stock Exchange (International))

Recent

price

4.31

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
NOK
- -
0.01
0.01
0.02
0.01
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.56
-0.71
-2.28
-4.07
-5.01
-5.7
-6.56
-7.26
-5.77
-4.53
-2.63
-0.15
-0.18
-0.17
-4.01
Basic EPS, GAAP
- -
-0.45
-0.61
-2.14
-3.59
-4.37
-4.89
-6.39
-6.89
-5.51
-4.15
-3.51
-0.37
-0.1
-0.36
-3.63
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.85
0.32
3.29
11.84
15.24
18.45
13.19
6.99
5.6
2.15
1.38
0.54
1.13
1.2
1.29
1.53
Book Value per Share
0.85
0.32
3.29
11.82
15.23
18.45
13.19
6.99
5.6
2.15
1.38
0.54
-0.05
0.19
0.54
1.53
Tangible Book Value per Share
24
24
24
28
42
47
52
51
60
72
97
118
175
236
332
108
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
-9,278.35
-5,917.48
-15,642.37
-41,898.17
-68,905.1
-104,808.61
- -
- -
- -
- -
- -
- -
- -
-15,866.51
- -
Operating Margin (%)
- -
1
- -
- -
1
1
1
2
13
15
11
11
1
2
21
10
Depreciation Expense
- -
-13
-17
-64
-173
-236
-294
-338
-434
-417
-441
-311
-27
-42
-58
-434
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-9,078.8
-5,558.02
-14,504.1
-39,605.26
-75,003.18
-97,289.4
- -
- -
- -
- -
- -
- -
- -
-13,214.58
- -
Profit Margin (%)
20
7
78
329
710
946
679
362
376
180
139
65
41
107
156
186
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
5
2
- -
- -
- -
- -
159
- -
LT Debt
20
8
79
330
713
949
680
363
388
179
141
64
272
337
456
183
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-95.5
-39.35
-31.14
-33.19
-28.34
-36.08
-64.78
-115.44
-147.2
-276.52
-304.6
-15.82
-13.86
-14.63
-155.9
Return on Common Equity (%)

Capital Structure

NOK

•

in mil. unless spec.
Dec'21
Mar'22
Jun'22
ST Debt
6
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
102
119
119
Market Capitalization
2,245
1,731
293

Working Capital

NOK

•

in mil. unless spec.
Dec'21
Mar'22
Jun'22
Total Current Assets
291
376
310
Cash, Cash Equivalents & STI
277
356
287
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
152
104
124
Payables & Accruals
- -
- -
- -
ST Debt
6
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

NOK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.03%
61.85%
35.25%
Free Cash Flow
36.72%
51.47%
400.22%
Net Income, GAAP
8.16%
-3.76%
37.44%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

NOK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

NOK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.18
2025
- -
- -
-0.17
2026
- -
- -
- -

Semi-annual Dividends Per Share

NOK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Thor Medical ASA, a Norway-based biotechnology company founded in 2017 and headquartered in Oslo, produces and supplies alpha-particle emitters for targeted cancer therapies using a proprietary process that separates naturally occurring radioactive decay products from thorium-232 (Th-232); its core products include thorium-228 (Th-228) as a precursor for lead-212 (Pb-212), radium-224 (Ra-224), and related alpha-emitting isotopes that enable radionuclide therapy (RNT) and radioligand therapy (RLT) with high energy deposition, short range, and minimal damage to healthy tissue. The company targets radiopharmaceutical developers and suppliers addressing unmet needs in oncology, including hard-to-treat solid tumors and hematological cancers such as lymphoma, leukemia, and metastasized prostate cancer; it operates primarily from Norway with its AlphaOne commercial-scale production facility under construction at Herøya Industripark, slated to commence thorium-based isotope output in the third quarter of 2026. Formerly known as Nordic Nanovector ASA, Thor Medical has pursued strategic growth through recent five-year supply agreements for Th-228, including partnerships with global radiopharmaceutical leader Telix Pharmaceuticals Limited in November 2025 to support Pb-212-based next-generation therapies and with NucliThera AS in November 2025 for hematological cancer programs led by veterans of FDA-approved alpha-emitter Xofigo; these deals expand its customer portfolio alongside prior commitments from Oncoinvent, AdvanCell, ARTBIO, and others, while pilot facilities established at Herøya in 2024 enable customer sample qualification and conversion of letters of intent into binding contracts.